Daily Endocrinology Research Analysis
Analyzed 101 papers and selected 3 impactful papers.
Summary
The most impactful papers identified three major advances in endocrinology: a newly defined vascular smooth muscle signaling mechanism for hypertension, a heparanase-dependent inflammatory pathway in type 1 diabetes, and a fasting-inducible mitochondrial carrier that regulates skeletal-muscle amino acid metabolism. Together, these studies provide mechanistic targets with potential relevance to hypertension, autoimmune diabetes, and metabolic adaptation.
Research Themes
- Novel molecular mechanisms and therapeutic targets in hypertension
- Inflammatory amplification and β-cell preservation in type 1 diabetes
- Mitochondrial metabolic adaptation during fasting
Selected Articles
1. RIMKLA promotes hypertension by activating PKM2 to trigger VSMC phenotype switch.
This multi-system mechanistic study identified RIMKLA as a previously unrecognized regulator of hypertension. RIMKLA acted as a scaffold linking PTP1B and PKM2, leading to PKM2 activation, enhanced glucose metabolism, reactive oxygen species production, ATP secretion, vascular smooth muscle cell phenotype switching, vasoconstriction, and elevated blood pressure.
Impact: The study defines a previously unknown RIMKLA–PTP1B–PKM2 axis that directly links vascular glucose metabolism to blood-pressure regulation. Genetic and pharmacological evidence positions RIMKLA and PKM2 as potential therapeutic targets for hypertension.
Clinical Implications: The findings may support development of therapies targeting RIMKLA, PKM2, or their interaction in resistant or metabolically driven hypertension. Clinical translation will require validation in human vascular tissues and prospective safety studies.
Key Findings
- RIMKLA expression was increased in arteries from patients and multiple animal models of hypertension.
- RIMKLA bound PTP1B and PKM2, promoting PTP1B Tyr66 phosphorylation and PKM2 Tyr105 dephosphorylation and activation.
- VSMC-specific RIMKLA overexpression increased vascular contractility and blood pressure, whereas RIMKLA or PKM2 deletion and PKM2 inhibition attenuated hypertension.
Methodological Strengths
- The mechanism was examined across human arteries, several hypertensive animal models, cultured cells, and genetically modified mice.
- The study combined vascular physiology, telemetry, myography, metabolomics, co-immunoprecipitation, mass spectrometry, and kinase-related biochemical assays.
Limitations
- The evidence is predominantly preclinical, and the causal relevance of RIMKLA in human hypertension remains unproven.
- The provided abstract does not report detailed sample sizes, treatment durations, or long-term toxicity and blood-pressure effects of pathway inhibition.
Future Directions: Future studies should assess RIMKLA expression and activity in well-phenotyped hypertensive patients, develop selective inhibitors, and determine whether vascular targeting can lower blood pressure without impairing systemic glucose metabolism.
BACKGROUND: Hypertension affects around one billion adults worldwide, with abnormal glucose metabolism and vascular smooth muscle cell (VSMC) phenotype switch playing crucial roles in its pathogenesis. Pyruvate kinase M2 (PKM2) is a key glycolytic enzyme, but its regulation and roles in VSMC phenotype switch and hypertension are unknown. Using the Gene Importance Calculator (GIC) to predict gene essentiality, we identified ribosomal modification protein rimK-like family member A (RIMKLA) as a highly relevant gene and explored its regulatory contributions to hypertension. METHODS: Internal mammary arteries from patients with hypertension and normotension, as well as arteries from angiotensin II (Ang II)-induced hypertensive mice, salt-sensitive hypertensive Dahl/SS rats, and spontaneously hypertensive rats, were analyzed in this study. Adenoviruses and adeno-associated viruses were used for ex vivo and in vivo gene overexpression. VSMC-specific RIMKLA or PKM2 knockout mice were generated using the Cre-Loxp system. Arterial tension was measured by wire myography, and blood pressure was assessed by the tail-cuff method and remote radio-telemetry. Protein-protein interactions were determined by co-immunoprecipitation with mass spectrometry. Non-targeted metabolomics, in vitro phosphorylation, adenosine triphosphate (ATP), reactive oxygen species (ROS), and cytoplasmic calcium assays were performed to identify the signaling axis involved.
2. Myeloid-Specific Heparanase Aggravates Insulitis in Type 1 Diabetes via Heparan Sulfate Fragment-Dependent Amplification of Macrophage Polarization.
This study establishes a mechanistic link between myeloid heparanase activity, intra-islet barrier disruption, and inflammatory macrophage polarization in type 1 diabetes. Both genetic and pharmacological HPSE inhibition preserved islet integrity and improved diabetes-related outcomes in experimental models.
Impact: The work identifies the HPSE–HS fragment–interferon-γ–STAT1 axis as a therapeutically actionable amplifier of insulitis. It offers a disease-modifying strategy that could complement immune modulation by protecting the islet microenvironment.
Clinical Implications: HPSE inhibition could eventually be investigated as an adjunctive therapy to preserve residual β-cell mass in type 1 diabetes, particularly near disease onset or during active insulitis. Human pharmacodynamic, safety, and immune-infection risk studies are required before clinical use.
Key Findings
- Myeloid-derived HPSE disrupted the intra-islet heparan sulfate barrier.
- Heparan sulfate fragments amplified interferon-γ–STAT1 signaling and promoted proinflammatory macrophage polarization.
- Genetic or pharmacological HPSE inhibition preserved islet integrity and ameliorated diabetes in experimental models.
Methodological Strengths
- The study integrates genetic and pharmacological perturbation to test both pathway causality and therapeutic tractability.
- It connects extracellular matrix barrier disruption with immune-cell signaling and disease-level outcomes.
Limitations
- The abstract does not provide detailed information on the experimental models, sample sizes, statistical effect estimates, or duration of follow-up.
- The translational relevance of HPSE inhibition in human type 1 diabetes, including infection and tissue-repair risks, remains uncertain.
Future Directions: Future research should validate the HPSE pathway in human pancreatic tissue and longitudinal type 1 diabetes cohorts, define the optimal timing and selectivity of inhibition, and test combination strategies with antigen-specific or immune-modulatory therapies.
The role of the heparanase (HPSE)-heparan sulfate (HS) axis in type 1 diabetes remains incompletely defined. We examined whether myeloid-derived HPSE drives islet inflammation, how HS fragments influence macrophage polarization, and whether pharmacological inhibition is protective. We found that myeloid HPSE disrupts the intraislet HS barrier and that the resulting HS fragments potentiate interferon-γ-STAT1 signaling to promote proinflammatory macrophage polarization. Genetic or pharmacological inhibition of HPSE preserved islet integrity and ameliorated diabetes, identifying this pathway as a potential therapeutic target in type 1 diabetes.
3. Mitochondrial control of amino acid catabolism by a fasting-inducible mitochondrial carrier.
This study identified SLC25A34 as a fasting-inducible mitochondrial carrier highly expressed in oxidative skeletal muscle. Biochemical reconstitution and tracer experiments showed that it imports phosphoenolpyruvate into the mitochondrial matrix, while loss of SLC25A34 selectively impairs glutamine-supported anaplerosis during nutrient deprivation without substantially disrupting glucose or pyruvate utilization.
Impact: The study reveals a previously unrecognized mitochondrial transport step that coordinates fasting-induced amino acid catabolism. This advances fundamental understanding of skeletal-muscle metabolic flexibility and may identify a target relevant to muscle wasting and metabolic disease.
Clinical Implications: The findings could inform future strategies to modulate muscle fuel selection during fasting, cachexia, sarcopenia, or metabolic disease. No immediate clinical intervention is supported because the evidence is currently mechanistic and preclinical.
Key Findings
- SLC25A34 was identified as a fasting-inducible mitochondrial carrier enriched in oxidative skeletal muscle.
- Bacterial reconstitution, proteo-liposome, and tracer studies showed that SLC25A34 transports phosphoenolpyruvate into the mitochondrial matrix.
- SLC25A34 loss impaired glutamine-supported anaplerosis during nutrient deprivation while largely preserving glucose and pyruvate utilization.
Methodological Strengths
- The study combines transporter reconstitution, proteo-liposome assays, isotope-tracer experiments, and tissue-specific genetic manipulation.
- It links a molecular transport activity to nutrient-dependent metabolic flux in skeletal muscle.
Limitations
- The provided abstract is truncated and does not report the complete in vivo phenotype, sample sizes, or quantitative effect estimates.
- The relationship between SLC25A34 activity and human metabolic disease, exercise adaptation, or muscle wasting remains unestablished.
Future Directions: Future studies should define the complete transport stoichiometry and regulatory biology of SLC25A34, evaluate its role in exercise and muscle wasting models, and determine whether pharmacological modulation can improve metabolic flexibility without causing mitochondrial toxicity.
Metabolic adaptation to nutrient deprivation requires coordinated control of mitochondrial anaplerosis and cataplerosis; however, how metabolite flux across the mitochondrial membrane is regulated during fasting remains less defined. Here, we report SLC25A34 as a fasting-inducible mitochondrial carrier that is highly expressed in oxidative skeletal muscle. Using bacterial reconstitution, proteo-liposomes, and tracer studies, we showed that SLC25A34 mediates the import of phosphoenolpyruvate (PEP) into the mitochondrial matrix. Loss of SLC25A34 impaired glutamine-supported anaplerosis under nutrient-deprived conditions, while glucose and pyruvate utilization remained largely intact. Muscle-specific deletion of